Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
During the last 20 years, an enormous research effort and hundreds of millions of dollars have been spent attempting to develop and prove that drugs may slow the rate of progression of Parkinson disease (PD). At the time of writing, no drug has yet satisfied the rigorous criteria set by clinicians and licensing authorities for a neuroprotective agent. Despite this apparent failure, numerous important lessons have been learned, and some areas for optimism have emerged. Dopaminergic drugs have, for 40 years, been the basis for the treatment of the predominant early motor features of PD. Several of these drugs have also demonstrated an ability to protect cells, including neurons, against a range of toxins that are of relevance to the pathogenesis of PD. Some have entered clinical trials for neuroprotection, and a few have produced a positive result according to the endpoint selected. The interpretation of these trials is the subject of some debate. A pattern has emerged in these and other clinical trials, which has lead to a novel concept for neuroprotection, and that is simply to treat early rather than delay. The basis for this may lie in the support of basal ganglia compensatory mechanisms and the restoration of normal dopaminergic transmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Self-citation
Cited by
PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin
Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D.-F., Gautier, C. A., Shen, J., Cookson, M. R., & Youle, R. J. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000298 · Cited by 2,944
“Parkinson disease is a common neurodegenerative disorder with no disease-modifying therapy presently available for its treatment [1].”
BackgroundCytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Cascade of immune mechanism and consequences of inflammatory disorders
Megha, K., Joseph, X., Akhil, V., & Mohanan, P. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153712 · Cited by 355
Perspectives on recent advances in the understanding and treatment of Parkinson's disease
Schapira, A. H., Agid, Y., Barone, P., Jenner, P., Lemke, M. R., Poewe, W., Rascol, O., Reichmann, H., & Tolosa, E. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02793.x · Cited by 69
Self-citation
Metadata
- Authors
- Schapira, A. H. V.
- Venue
- Neurology
- Published
- 2009-02-17
- Volume
- 72
- Issue
- 7_supplement_2
- Pages
- S44-50
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2120200579
- Cited by
- 67
- References
- 1
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181990438
- The paper
- Schapira, A. H. V. (2009). Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0b013e3181990438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.